Dow Jones

38 807,33

0,25%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Royaume-Uni
LSE
Bergenbio Asa (0RU5)
Bergenbio Asa (0RU5) Actualités

0RU5

Bergenbio Asa (0RU5)

Bergenbio Asa

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:LSE:0RU5

1 2 3 4 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
22/08/2023	10h50	PR Newswire (US)	BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer	LSE:0RU5	Bergenbio Asa
26/05/2023	15h07	PR Newswire (US)	BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue	LSE:0RU5	Bergenbio Asa
25/04/2023	18h26	PR Newswire (US)	BerGenBio ASA: Proposed partially underwritten rights issue	LSE:0RU5	Bergenbio Asa
18/04/2023	07h23	PR Newswire (US)	BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR	LSE:0RU5	Bergenbio Asa
09/03/2023	11h22	PR Newswire (US)	BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations	LSE:0RU5	Bergenbio Asa
16/02/2023	07h32	PR Newswire (US)	BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update	LSE:0RU5	Bergenbio Asa
15/02/2023	17h35	PR Newswire (US)	BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	LSE:0RU5	Bergenbio Asa
02/02/2023	07h17	PR Newswire (US)	BerGenBio Announces the Establishment of Oncology Scientific Advisory Board	LSE:0RU5	Bergenbio Asa
15/11/2022	07h10	PR Newswire (US)	BerGenBio reports third quarter 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
25/10/2022	07h37	PR Newswire (US)	BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS	LSE:0RU5	Bergenbio Asa
11/10/2022	07h36	PR Newswire (US)	BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	LSE:0RU5	Bergenbio Asa
27/09/2022	15h31	PR Newswire (US)	BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS	LSE:0RU5	Bergenbio Asa
23/08/2022	07h36	PR Newswire (US)	BerGenBio reports second quarter and half year 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
04/05/2022	07h29	PR Newswire (US)	BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19	LSE:0RU5	Bergenbio Asa
26/04/2022	07h13	PR Newswire (US)	BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET	LSE:0RU5	Bergenbio Asa
11/04/2022	07h12	PR Newswire (US)	BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer	LSE:0RU5	Bergenbio Asa
07/04/2022	14h20	PR Newswire (US)	BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021	LSE:0RU5	Bergenbio Asa
16/02/2022	07h09	PR Newswire (US)	BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021	LSE:0RU5	Bergenbio Asa
27/01/2022	07h21	PR Newswire (US)	BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients	LSE:0RU5	Bergenbio Asa
09/11/2021	14h19	PR Newswire (US)	BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC)	LSE:0RU5	Bergenbio Asa
09/11/2021	14h18	PR Newswire (US)	Bergenbio Presents Pre-clinical and Clinical Data on Bemcentinib in STK11-positive NSCLC at SITC Annual Meeting 2021	LSE:0RU5	Bergenbio Asa
12/07/2021	14h31	PR Newswire (US)	BerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMID	LSE:0RU5	Bergenbio Asa
11/06/2021	09h38	PR Newswire (US)	Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting	LSE:0RU5	Bergenbio Asa
18/05/2021	07h21	PR Newswire (US)	BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients	LSE:0RU5	Bergenbio Asa
19/04/2021	07h26	PR Newswire (US)	BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients	LSE:0RU5	Bergenbio Asa
06/03/2021	14h59	PR Newswire (US)	BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021)	LSE:0RU5	Bergenbio Asa
04/03/2021	07h22	PR Newswire (US)	Bergenbio Closes Recruitment Into Trial Assessing Bemcentinib In Covid-19 Patients	LSE:0RU5	Bergenbio Asa
17/02/2021	07h20	PR Newswire (US)	BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021)	LSE:0RU5	Bergenbio Asa
06/12/2020	20h23	PR Newswire (US)	BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020	LSE:0RU5	Bergenbio Asa
11/11/2020	14h21	PR Newswire (US)	BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting	LSE:0RU5	Bergenbio Asa